Medical Condition

myelodysplastic syndrome

Total Trials

10

Recruiting Now

10

Trial Phases

Phase 1, Phase 2, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for myelodysplastic syndrome sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — myelodysplastic syndrome Clinical Trials

How many clinical trials are currently recruiting for myelodysplastic syndrome?

ClinicalMetric currently tracks 10 actively recruiting clinical trials for myelodysplastic syndrome, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 10. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.

What trial phases are available for myelodysplastic syndrome?

myelodysplastic syndrome research spans Phase 1 (6 trials), Phase 2 (3 trials). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.

How do I find out if I qualify for a myelodysplastic syndrome clinical trial?

Eligibility criteria for myelodysplastic syndrome trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.

Trial Phases

Phase 1

Phase 2

Top Sponsors

City of Hope Medical Center 2 trials

University of Michigan Rogel Cancer Center 1 trial

Institute of Hematology & Blood Diseases Hospital, China 1 trial

Laguna Biotherapeutics, Inc. 1 trial

Fred Hutchinson Cancer Center 1 trial

Recruiting Clinical Trials

NCT07737769 Phase 1

Recruiting

Arsenic Trioxide to Prevent Relapse in Patients Undergoing Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia or Myelodysplastic Syndrome

University of Michigan Rogel C...

View Trial →

NCT06543381 Phase 1

Recruiting

Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant

City of Hope Medical Center

View Trial →

NCT04645199

Recruiting

National Longitudinal Cohort of Hematological Diseases

Institute of Hematology & Bloo...

View Trial →

NCT07573111 Phase 1

Recruiting

Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation

Laguna Biotherapeutics, Inc.

View Trial →

NCT07046078 Phase 2

Recruiting

Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer

Fred Hutchinson Cancer Center

View Trial →

NCT03471260 Phase 1, Phase 2

Recruiting

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

M.D. Anderson Cancer Center

View Trial →

NCT02508038 Phase 1

Recruiting

Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

University of Wisconsin, Madis...

View Trial →

NCT07763054

Recruiting

Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients

Haikou Affiliated Hospital of ...

View Trial →

NCT04167696 Phase 1

Recruiting

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02

Enrollment

27 pts

Location

United States, Belgi...

Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome

City of Hope Medical Center

View Trial →

Related Conditions

acute myeloid leukemia (9) acute lymphoblastic leukemia (3) chronic myelomonocytic leukemia (2) multiple myeloma (2) lymphoma (2) hemophilia (1) hemophilia a (1) hemophilia b (1) mds (1) leukemia (1) aplastic anemia (1) bleeding disorder (1)

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology